Description
What is Jakauto® Tofacitinib Ointment
Jakauto Ointment suppresses the overactive immune system by inhibiting certain enzymes called Janus kinases (JAKs). Thus, Jakauto Ointment blocks the production of pro-inflammatory substances (including cytokines) that contribute to the development of inflammation and other symptoms of atopic dermatitis. When used for androgenetic alopecia, Jakauto Ointment prevents the destruction of hair follicles by an overactive immune system. Applying Jakauto Ointment helps in hair regrowth in areas affected by androgenetic alopecia.
Jakauto® Tofacitinib Ointment treats atopic dermatitis and hair loss (androgenetic alopecia). It works by blocking the release of certain chemical messengers that cause redness, swelling, and itching or cause hair shedding in the affected area.
Jakauto® Tofacitinib Ointment should be used in the dose and duration your doctor prescribes. This medicine should be used regularly to get the most benefit from it. Do not use more than you need, it will not clear your condition faster and may cause undesirable side effects.
This medicine is usually safe to use and does not usually cause any side effects. However, if you experience any symptoms on using the medicine, let your doctor know. They may suggest ways to minimize or treat the side effects.
It is not likely that other medicines you take by mouth or injection will affect the way this medicine works, but talk to your doctor before using it if you have recently used another medicine that contains a steroid or had an allergic reaction to another medicine. Pregnant and breastfeeding mothers should consult their doctors before using this medicine.
Tofacitinib for Vitiligo
Tofacitinib is currently being studied for use in Vitiligo. One of the central pathways of vitiligo that seems to be important to the disease progression is the interferon-gamma signaling pathway. Involved in this pathway are the JAK receptors. Because of this, the use of a JAK receptor can be used to block the pathway and therefore block the progression of the disease and help induce repigmentation.
Efficacy studies have been done of Tofacitinib oral for the treatment of vitiligo. A small, retrospective study done in 2017 of the use of oral Tofacitinib for vitiligo studied the use in 10 patients. Only five of these patients had a response and it was noted that response was better on the sun-exposed areas of the skin. Because of this, it was recommended that Tofacitinib be used in combination with phototherapy.
A more recent article outlining two successful case reports show more promise for the use of Tofacitinib in vitiligo. Case one reports a patient used Tofacitinib 5mg twice daily concomitantly with full-body NB-UVB phototherapy on her face. Vitiligo had affected 75% of her face and after three months of treatment, she had regained pigmentation in almost her entire face.
Case two outlines a male patient who had pigmentation loss in 90% of his face. He also used Tofacitinib 5mg twice daily with full-body NB-UVB phototherapy. After three months, he regained 50% repigmentation in his face and after six months he regained 75% repigmentation.
All of these studies show that concomitant use of phototherapy with Tofacitinib yielded the best results. Additionally, repigmentation mostly occurred on the facial reasons of these patients and there was very little to no repigmentation of the rest of the body. Due to this fact, studies involving Tofacitinib as a topical cream have emerged in the last year.
Topical Tofacitinib has been studied the past couple of years for use in alopecia however there are not yet published studies about its use for vitiligo. According to clinicltrials.gov, a study concluded last year on the use of topical Tofacitinib in vitiligo, however, the article outlining the results of the study has not yet been published. As previously mentioned, another JAK inhibitor, Ruxolitinib, has been studied for topical use in vitiligo. Because of this and the results of the trials involving oral Tofacitinib, there is currently a theoretical use of topical Tofacitinib for use in vitiligo.
Benefits of Jakauto® Tofacitinib Ointment
In Treatment of Atopic dermatitis. Jakauto Ointment helps manage the symptoms of atopic dermatitis such as dry, itchy, swollen, and red skin. It reduces dryness and keeps the skin hydrated and moisturized. Apply Jakauto Ointment to the affected area as directed by your doctor to get the most benefit.
In Treatment of Hair Loss. Jakauto Ointment is a medicine used to treat hair loss. It prevents further hair loss and helps hair to regrow. This increases hair density in the affected area. You need to continue using Jakauto Ointment as advised by your doctor to enjoy its benefit. Regrowth of hair can be beneficial to your mood, self-esteem as well as your appearance.
Tofacitinib Topical Ointment: On-Label and Off-Label Usage
On-Label Usage
Tofacitinib is a Janus kinase (JAK) inhibitor primarily used in oral form to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. The topical form of Tofacitinib, however, is specifically formulated for the treatment of mild to moderate plaque psoriasis.
Indication:
Plaque Psoriasis: Tofacitinib topical ointment is indicated for the treatment of mild to moderate plaque psoriasis in adults. This chronic autoimmune condition is characterized by red, scaly patches on the skin, and the JAK inhibitor works by modulating the immune response and reducing inflammation.
Off-Label Usage
Off-label use refers to the practice of prescribing pharmaceuticals for an unapproved indication or in an unapproved age group, dosage, or route of administration. Although Tofacitinib topical ointment is officially approved only for plaque psoriasis, clinicians may use it for other conditions based on emerging research and clinical judgment.
Potential Off-Label Indications:
Atopic Dermatitis (Eczema): Some studies suggest that Tofacitinib topical ointment can be effective in reducing symptoms of atopic dermatitis, such as itching and inflammation. This is due to its immunomodulatory effects, which can help manage the overactive immune responses seen in eczema.
Vitiligo: There is growing evidence that JAK inhibitors, including Tofacitinib, might help in the repigmentation of vitiligo patches. The topical ointment may help restore skin color by modulating the immune system and inhibiting the pathways responsible for depigmentation.
Alopecia Areata: Tofacitinib has shown promise in promoting hair regrowth in patients with alopecia areata, an autoimmune condition that causes hair loss. While oral Tofacitinib is more commonly studied for this purpose, the topical form may also be beneficial, particularly for localized patches.
Lichen Planus: This inflammatory condition affecting the skin and mucous membranes may respond to Tofacitinib ointment due to its anti-inflammatory properties.
Other Dermatologic Conditions: Other chronic inflammatory skin conditions, such as discoid lupus erythematosus and certain forms of chronic urticaria, might also benefit from Tofacitinib ointment, though the evidence is currently limited and more research is needed.
Considerations and Precautions
Safety and Efficacy: While off-label uses can be promising, they also carry risks due to the lack of extensive clinical trials. The safety profile for these uses is not as well established as for on-label indications.
Monitoring: Patients using Tofacitinib, whether for on-label or off-label purposes, should be regularly monitored for potential side effects, such as local skin reactions or systemic absorption leading to broader immune suppression.
Patient Selection: Careful patient selection and a thorough understanding of the patient’s medical history are crucial in determining the appropriateness of off-label use.
In summary, Tofacitinib topical ointment is officially approved for the treatment of mild to moderate plaque psoriasis. However, its immunomodulatory properties make it a candidate for off-label use in other dermatologic conditions, such as atopic dermatitis, vitiligo, and alopecia areata. Clinicians must weigh the potential benefits against the risks and ensure careful monitoring when prescribing Tofacitinib for off-label uses.
Reviews
There are no reviews yet.